These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18753079)

  • 1. [In vitro induced and expanded Epstein Barr virus-specific cytotoxic T lymphocytes can specifically kill nasopharyngeal carcinoma cells].
    Chen LP; Huang JQ; Zhou TC; Zhang SX; Wang JL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1431-3. PubMed ID: 18753079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined transfection with EBV-specific epitopes and HLA-A2 genes is more effective than separate transfection in promoting CTL lysis against nasopharyngeal carcinoma.
    Ding W; Fong C
    Cell Mol Immunol; 2004 Jun; 1(3):229-34. PubMed ID: 16219173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines.
    Wang EC; Lehner PJ; Graham S; Borysiewicz LK
    Eur J Immunol; 1994 Nov; 24(11):2903-9. PubMed ID: 7525311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.
    Xu JJ; Yao K; Yu CJ; Chen X; Lu MP; Sun H; Li BZ; Ding CN; Zhou F
    Auris Nasus Larynx; 2006 Dec; 33(4):441-6. PubMed ID: 16934422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
    Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
    Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
    Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
    Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
    Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
    Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
    J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
    Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
    Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Change and effect of Epstein Barr virus (EBV) antigen induced T8 cells in nasopharyngeal carcinoma patients and EBV seropositive individuals].
    Huang PC
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):12-6. PubMed ID: 8392927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood.
    Sun Q; Burton RL; Pollok KE; Emanuel DJ; Lucas KG
    Cell Immunol; 1999 Aug; 195(2):81-8. PubMed ID: 10448007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.